Ningaloo Biosystems

Ningaloo Biosystems is a Munich-based biotech startup founded in 2020, developing a novel optogenetic platform for industrial bioproduction. Their core technology uses light to precisely control gene expression and cellular activity in production cell lines like CHO and HEK, enabling dynamic, tunable manufacturing of complex biologics. This approach seeks to address key bottlenecks in biopharma manufacturing—cost, scalability, and product quality—with the goal of making next-generation therapies more affordable and widely available. The company is in the platform development and validation stage, collaborating with academic partners and generating proof-of-concept data for applications like bispecific antibody production.

Proprietary optogenetic platform using light-controlled gene expression to dynamically regulate bioproduction processes in mammalian cell lines (e.g., CHO, HEK) for manufacturing complex biologics.

Ningaloo competes in the advanced bioprocessing space against companies developing high-throughput cell line engineering, continuous bioprocessing systems, and AI/ML-based process optimization tools. Its unique differentiator is the real-time, dynamic control offered by optogenetics, a more direct and tunable method than traditional chemical or metabolic induction systems used in bioproduction.